Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Conditions

Colorectal Neoplasms 317Squamous Cell Carcinoma of Head and Neck 168Head and Neck Neoplasms 150Carcinoma, Non-Small-Cell Lung 97Colonic Neoplasms 90Rectal Neoplasms 82Neoplasm Metastasis 72Neoplasms 60Pancreatic Neoplasms 40Carcinoma, Squamous Cell 40Lung Neoplasms 35Esophageal Neoplasms 25Breast Neoplasms 22Stomach Neoplasms 20Recurrence 20Carcinoma 18Laryngeal Neoplasms 17Tongue Neoplasms 16Mouth Neoplasms 16Oropharyngeal Neoplasms 14Esophageal Squamous Cell Carcinoma 14Salivary Gland Neoplasms 12Adenocarcinoma Of Esophagus 12Hypopharyngeal Neoplasms 11Colorectal Cancer Metastatic 11Laryngeal Diseases 10Adenocarcinoma of Lung 10Uterine Cervical Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 9Ovarian Neoplasms 9

Interventions

Surveys and Questionnaires 5pazopanib 3Erlotinib Hydrochloride 3Cetuximab 3Vorinostat 2Oxaliplatin 2Bevacizumab 2Azacitidine 2temsirolimus 1satraplatin 1ridaforolimus 1ixazomib 1X-Rays 1Videotape Recording 1Valproic Acid 1Trastuzumab 1Sugars 1Sorafenib 1Platinum 1Pemetrexed 1Magnetic Resonance Spectroscopy 1Leucovorin 1Lenalidomide 1Lapatinib 1LY 2275796 1Injections, Subcutaneous 1Fluorouracil 1Everolimus 1Curcumin 1Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Advanced Cancers × Cetuximab × Clear all
NCT00941499 2015-11-18

Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab

M.D. Anderson Cancer Center

Phase 1 Completed
140 enrolled

Advanced Cancers

NCT00895362 2015-07-13

Erlotinib in Combination With Cetuximab

M.D. Anderson Cancer Center

Phase 1 Completed
65 enrolled

Advanced Cancers

NCT01432119 2013-04-09

Phase 1 Trial With SIR-Spheres and Cetuximab +/- Erlotinib

M.D. Anderson Cancer Center

Phase 1 Withdrawn

Advanced Cancers

Data powered by HemOnc (CC BY 4.0) Colophon âš¡